SPRINGWORKS THERAPEUTICS INC. - COMMON STOCK

SpringWorks Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

04 Jan 2022 06:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Clinical Collaboration with AbbVie to Evaluate Nirogacestat in Combination with ABBV-383 in Patients with Relapsed or Refractory Multiple Myeloma

10 Dec 2021 06:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b/2 Trial Evaluating Nirogacestat in Combination with Elranatamab (PF-06863135) in Patients with Relapsed or Refractory Multiple Myeloma

06 Dec 2021 06:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Full Enrollment of Phase 2b ReNeu Trial Evaluating Mirdametinib in Adult and Pediatric Patients with NF1-Associated Plexiform Neurofibromas

29 Nov 2021 06:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics to Participate in the 4th Annual Evercore ISI HealthCONx Conference

23 Nov 2021 06:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Reports Third Quarter 2021 Financial Results and Recent Business Highlights

04 Nov 2021 06:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces the Initiation of an Expanded Phase 2 Cohort and Addition of New Sub-Studies to Existing Clinical Collaboration with GlaxoSmithKline Evaluating Nirogacestat in Combination with BLENREP in Patients with Relapsed or Refractory Multiple Myeloma

27 Oct 2021 06:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics to Collaborate with Ab Magnitude on Target Identification and Discovery of Next-Generation Targeted Oncology Therapeutics

20 Oct 2021 06:45:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics to Collaborate with Leading Academic Institutions to Advance Portfolio of Next-Generation Mutation-Selective EGFR Inhibitors

20 Oct 2021 06:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

07 Sep 2021 06:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Enters into Research Collaboration with Leading Cancer Institute to Further Evaluate Nirogacestat as a BCMA Potentiator in Multiple Myeloma

30 Aug 2021 06:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Highlights

04 Aug 2021 06:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics to Present at the 12th Annual Wedbush PacGrow Healthcare Conference

03 Aug 2021 09:00:01 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Phase 1b/2a Clinical Trial of Mirdametinib in Patients with Advanced Solid Cancers Harboring MAPK-Activating Mutations

03 Aug 2021 06:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Appoints Dr. James Cassidy as Chief Medical Officer

27 Jul 2021 08:00:01 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Issuance of New U.S. Composition of Matter Patent to Polymorphic Form of Mirdametinib, Extending Patent Protection Into 2041

20 Jul 2021 07:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Initiation of Phase 1/2 Clinical Trial of Mirdametinib in Children and Young Adults with Low-Grade Glioma

16 Jun 2021 06:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Presentation of Updated Interim Data from the Phase 2b ReNeu Trial at the 2021 Children’s Tumor Foundation NF Conference

15 Jun 2021 16:05:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Clinical Collaboration with Seagen to Evaluate Nirogacestat in Combination with SEA-BCMA in Patients with Relapsed or Refractory Multiple Myeloma

07 Jun 2021 06:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

01 Jun 2021 06:30:00 By Nasdaq GlobeNewswire